New–Generation Antipsychotics Long–Acting Injectable Formulations and Drug–Delivery Technologies

Samir Ahmad; Archna Roy; Shaila Angela Lewis

Volume : IV, Issue : XII, December - 2015

New–Generation Antipsychotics Long–Acting Injectable Formulations and Drug–Delivery Technologies

Samir Ahmad, Archna Roy, Shaila Angela Lewis

Abstract :

Compliance is a major problem in the treatment of schizophrenia. Several oral second–generation antipsychotics drugs are available for schizophrenia management. Non–compliance and limited availability as oral drugs limits the benefits. Second–generation antipsychotics long–acting injectable (LAIs) shows more controlled treatment of negative symptoms of schizophrenia and better therapy adherence as compared to first–generation LAIs. Various new innovative technologies that utilize fully bioresorbable/biodegradable polymers as a long acting polymers which allow for increased performance of new and existing pharmaceutical drugs for the development of LAIs, which includes Medisorb�, Monospheres�, and SABER� depot technologies.